Breast cancer vaccine looks safe, study shows

A therapeutic vaccine designed for breast cancer appears to be safe in women with advanced disease and shows signs of actually slowing down tumor growth, U.S. researchers reported on Friday. Dendreon Corporation, maker of the Provenge prostate cancer vaccine, calls the new vaccine Neuvenge. It targets a type of breast cancer called her2/neu-positive breast cancer, which affects between 20 percent and 30 percent of breast cancer patients. Like Provenge, Neuvenge is made using immune cells from the cancer patient, so it is a tailor-made vaccine. --Click the title of this post to read the full article from its source--

HER2 Vaccine May Reduce Breast Cancer Recurrence

According to results recently presented at the 2006 annual San Antonio Breast Cancer Symposium (SABCS), an experimental HER2 vaccine may reduce the risk of cancer recurrence in some women with high-risk early breast cancer. Although cure rates remain high for patients with early breast cancer, particularly women with node-negative breast cancer, some of these women will experience a cancer recurrence and may ultimately succumb to their disease. Therefore, a reduction in the risk of recurrence among high-risk women is warranted. HER2 is a protein that is overexpressed in twenty to thirty percent of breast cancers. Using a part of the HER2 protein (the E75 peptide), researchers have developed an experimental anticancer vaccine. --Click the title of this post to read the full article from its source--